LUCIUS 卢修斯 普拉替尼 Pralsetinib肺癌、甲状腺癌

普拉替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Pralsetinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

psule contains: Pralsetinib .... 100mg

LUCIUS
MACEUTICALS

肺癌、甲状腺癌

Lucirfal is a kinase inhibitor indicated for treatment o
1.duun Pouicinis wiu inctaslane rearranged during
ransfection(RET) fusion-positive non-small cell
lung cancer as detected by an FDA approved test
. Adit and pediathe paulenis 12 ycars ol a geanu

LuciPral

iutt wit auvanced of metastatic KEI-mutan
cuunary myroia cancer (MTC) who teoni
3. Adult and nadiatst

Pralsetinib Capsules

sovanced or metastatic RET fission-nositiv
require systemic theraoy and who

RET fusIon-positve

Rx Only

ve fodine.refractory
u cosage in adults and nedialne

100mg

FDA批准

on an emoty stomachina fu
stomach(no tood intake tor at keastL
nours before and at leget I hour aftor talino l uePra
Cansule should he scssllatred nole & nat chewcao

crushed.
orage: in a dry place and store at 20℃ to 25C.
Warning:
Warning:
Keep medicine out of the reach of Children. Do no
adiinistered LuciPral in Pregnancy and Lactation
patient treatment.
PLEASE SEE PACKAGE INSE
Manufactured and Marketed b

LUCIUS

权威认证

Thongmang village, Xaythany district,
Vientiane Capital, Laos
o be sold by retatl on prescription

by the nhyoogist only and

onty, and as tirectcd

120 Capsules

口碑质量

适应症:

1、转染基因(RET)融合阳性的非小细胞肺癌癌症过程中转移性重
排的成年患者;
2、12岁及以上患有晚期或转移性RET-毛髓样甲状腺癌症
MTC)的成人和儿童患者;
3、12岁及以上患有晚期或转移性RET融合阳性甲状腺癌症的成人
和儿童患者,需要全身治疗,且放射性碘难治(如果放射性碘合适)。

推荐剂量:

1、成人和12岁及以上儿童患者的推荐剂量为:每日一次,每次
400mg;2、空腹口服(餐前1小时或餐后2小时)